

## REMARKS

Without acquiescing in any rejection, applicants propose to amend claims 1, 11, 12 and 26. Applicants also cancel claim 25 without prejudice or disclaimer. Applicants amend the claims to recite "immunogenic", meaning that the agents and composition are capable of eliciting immune responses, such as the proliferation of T-cells or the generation of an antibody response. The agents and compositions also have been shown to decrease or partially stabilize PSA (prostate specific antigen) levels in cancer patients. See Figure 4. In the absence of the recited agents or compositions, PSA levels rise, often exponentially. See page 11 of applicants' specification.

Applicants also provide a declaration from Dr. Jonathan Davies. Dr. Davies explains that EP 0 877 798 B1, which was granted on May 7, 2003, discloses ATCC CRL-12037 (NIH-1542 cells). By virtue of the grant of the European patent, the European Patent Office (EPO) requires the ATCC, as a Budapest Treaty International Depository Authority, to make the deposit accessible to the public. See Tab 1 of Dr. Davies declaration. Accordingly, the ATCC must provide a sample of the deposit, and therefore the NIH-1542 cells are publicly available.

The cells also are available from the U.S. Government through the National Cancer Institute. See Nishimura *et al.*, *Cancer Res.* 59: 6230-38 (1999); U. S. Patent No. 6,699,483 at Table 1; Bright *et al.*, *Cancer Res.* 57: 995-1002 (1997). Accordingly, there can be no doubt that NIH-1542 cells are publicly available.


The recited combination of cell lines is an example where cell lines were selected so as to facilitate haplotype mismatch, which is nowhere taught or suggested by the prior

art. Applicants reserve the right to claim other combinations in accordance with applicants' invention.

**REQUESTED RELIEF**

Applicants respectfully request entry of the amendments, which were made without prejudice, and allowance of the claims. The examiner is invited to contact the undersigned should there be any questions.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "John P. Isacson", written over a horizontal line.

John P. Isacson  
Attorney for Applicants

February 10, 2005

HELLER EHRMAN WHITE & MCAULIFFE Registration No. 33,715  
1666 K Street, N.W., Suite 300  
Washington, DC 20006  
Telephone: (202) 912-2000  
Facsimile: (202) 912-2020  
Customer No. 26633